Sign in

AZTA on Nasdaq

Azenta Life Sciences

Logo: https://www.azenta.com./, Non-free logo, via Wikipedia5

Semiconductor Manufacturer

Azenta, (formerly Brooks Automation) was founded in 1978, and is based in Burlington, Massachusetts, United States. The company is a provider of life sciences services including genomics, cryogenic storage, automation, and informatics.3 It employed 1,176 people in 2023.1 Its revenue was $555 million in 2022.1 Its shares trade on Nasdaq under the symbol AZTA.1 Wikipedia text CC BY-SA 4.0

Price unavailable

Last updated Oct 21, 2026.

Overview

$593.8MRevenue, fiscal 20256
-$55.8MNet income, fiscal 20256

Compare with Veeco, Cricut or Axcelis Technologies, or pick any stock.

  • TickerAZTA on Nasdaq1
  • Industrybiotechnology1
  • HeadquartersBurlington1
  • Websitewww.azenta.com
  • Legal formDelaware corporation1
  • Incorporated inDE7
  • Business address200 Summit Drive, 6Th Floor, Burlington, Ma 018037
  • Filer categoryLarge accelerated filer7
  • LEI35ZN6X1ANPH25YN32Y174
  • StatusActive4
  • LEI statusLapsed (not renewed)4
  • Registered addressC/O CORPORATION SERVICE COMPANY, 19808 Wilmington, United States4
  • Registered withDivision of Corporations, Department of State, 24484464

See how the biggest companies compare on our leaderboards

Azenta, (formerly Brooks Automation) was founded in 1978, and is based in Burlington, Massachusetts, United States. The company is a provider of life sciences services including genomics, cryogenic storage, automation, and informatics.3

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

45.5%Gross margin6
-4.5%Operating margin6
-9.4%Net margin6
3.6%Revenue growth, 20256
-3.2%Return on equity6
$38.3MFree cash flow6

What sells

Revenue by product, business segment and region, as the company reports it to the SEC.

Products and services

Service brought in 71% of the revenue Azenta Life Sciences broke down this way in fiscal 2025.

  1. Service$420.6M671%up 5% from 2024
  2. Product$173.2M629%down 0% from 2024
Products and services by year
Products and services202320242025
Service$375.4M$399.7M$420.6M
Product$176.1M$173.7M$173.2M

Business segments

Multiomics brought in 45% of the revenue Azenta Life Sciences broke down this way in fiscal 2025.

  1. Multiomics$269.2M645%up 6% from 2024
  2. Core Products$197.6M633%up 1% from 2024
  3. Sample Repository Solutions$127.0M621%up 4% from 2024
Business segments by year
Business segments202320242025
Multiomics$248.3M$254.6M$269.2M
Core Products$192.1M$196.5M$197.6M
Sample Repository Solutions$111.1M$122.4M$127.0M

Regions

United States brought in 61% of the revenue Azenta Life Sciences broke down this way in fiscal 2025.

  1. United States$365.0M661%down 0% from 2024
  2. Europe$107.4M618%up 13% from 2024
  3. China$58.3M610%up 0% from 2024
  4. United Kingdom$35.4M66%up 30% from 2024
  5. Asia Pacific$23.3M64%up 9% from 2024
  6. Other$4.4M61%down 32% from 2024
Regions by year
Regions202320242025
United States$351.4M$365.1M$365.0M
Europe$87.2M$95.2M$107.4M
China$52.1M$58.2M$58.3M
United Kingdom$26.7M$27.2M$35.4M
Asia Pacific$25.6M$21.3M$23.3M
Other$8.5M$6.5M$4.4M

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Cost of revenue50¢$323.5M
  • Research and development5¢$30.4M
  • Selling, general and admin40¢$261.6M
  • Income tax5¢$31.6M

Out of $593.8M in revenue.6 The company lost money this year.

Where each dollar of operating cash went, fiscal 2025

  • Capital spending47¢$33.9M
  • Kept or used elsewhere53¢$38.3M

Out of $72.2M of cash from operations.6

Financial statements

Revenue10111213146$593.8M in 2025−6% since 2018
0$200.0M$400.0M$600.0M$800.0M2018: $631.6M$631.6M20182019: $334.2M$334.2M2019−47%2020: $388.5M$388.5M2020+16%2021: $513.7M$513.7M2021+32%2022: $555.5M$555.5M2022+8%2023: $551.5M$551.5M2023−1%2024: $573.4M$573.4M2024+4%2025: $593.8M$593.8M2025+4%
Gross profit10111213146$270.3M in 2025+10% since 2018
0$100.0M$200.0M$300.0M2018: $246.1M$246.1M20182019: $134.6M$134.6M2019−45%2020: $172.1M$172.1M2020+28%2021: $243.8M$243.8M2021+42%2022: $255.6M$255.6M2022+5%2023: $239.2M$239.2M2023−6%2024: $254.6M$254.6M2024+6%2025: $270.3M$270.3M2025+6%
Operating income10111213146-$26.8M in 2025
-$75.0M-$50.0M-$25.0M0$25.0M$50.0M2018: $31.4M$31.4M20182019: -$47.4M-$47.4M20192020: -$36.6M-$36.6M2020−23%2021: -$31.1M-$31.1M2021−15%2022: -$24.7M-$24.7M2022−20%2023: -$61.2M-$61.2M2023+148%2024: -$51.3M-$51.3M2024−16%2025: -$26.8M-$26.8M2025−48%
Net income10111213146-$55.8M in 2025
-$1.0B0$1.0B$2.0B$3.0B2018: $116.6M$116.6M20182019: $437.4M$437.4M2019+275%2020: $64.9M$64.9M2020−85%2021: $110.7M$110.7M2021+71%2022: $2.1B$2.1B2022+1826%2023: -$14.6M-$14.6M20232024: -$164.9M-$164.9M2024+1027%2025: -$55.8M-$55.8M2025−66%

Every line of the income statement as filed: the last 3 fiscal years (annual) or 8 quarters (quarterly), latest first.6

Period ending2025-09-302024-09-302023-09-30
Total revenue$593.8M$573.4M$551.5M
Total cost of revenue$323.5M$318.8M$312.3M
Gross profit$270.3M$254.6M$239.2M
Research and development$30.4M$31.5M$32.1M
Selling, general and administrative$261.6M$263.0M$263.7M
Impairment of goodwill and intangible assets$0$4.7M$0
Restructuring charges$5.2M$6.8M$4.6M
Total operating expenses$297.1M$305.9M$300.5M
Operating loss-$26.8M-$51.3M-$61.2M
Interest income, net$18.8M$32.9M$43.5M
Other income (expense), net$922.0K-$732.0K-$2.3M
Loss from continuing operations before income taxes-$7.1M-$19.1M-$20.0M
Income tax (benefit) expense-$31.6M$5.2M-$12.0M
Income (loss) from continuing operations$24.5M-$24.4M-$8.0M
Loss from discontinued operations, net of tax-$80.2M-$140.5M-$6.6M
Net loss-$55.8M-$164.9M-$14.6M
Income (loss) from continuing operations (in dollars per share)$1-$0-$0
Loss from discontinued operations, net of tax (in dollars per share)-$2-$3-$0
Net loss per share (in dollars per share)-$1.22-$3.10-$0.22
Income (loss) from continuing operations (in dollars per share)$1-$0-$0
Loss from discontinued operations, net of tax (in dollars per share)-$2-$3-$0
Diluted net loss per share (in dollars per share)-$1.22-$3.10-$0.22
Basic (in shares)45.7M shares53.2M shares66.3M shares
Diluted (in shares)45.9M shares53.2M shares66.3M shares

Compare Azenta Life Sciences with another company

Corporate structure

Azenta Life Sciences sits at the top of its group. 26 entities, 13 countries on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Azenta Life Sciences

  • Azenta Life Sciences Burlington, Massachusetts, United States
    • Azenta (Guangzhou) Life Science Co., Ltd. Subsidiary · China
    • Azenta (Nanjing) Life Science Technologies Co., Ltd. Subsidiary · China
    • Azenta (Shanghai) Life Science Co. Ltd. Subsidiary · China
    • Azenta (Tianjin) Biotechnology Co., Ltd. Subsidiary · China
    • Azenta Beijing Technologies Limited Subsidiary · China
    • Azenta Germany GmbH Subsidiary · Germany
    • Azenta Japan Corp. Subsidiary · Japan
    • Azenta Life Sciences Canada, Inc. Subsidiary · Canada
    • Azenta Luxembourg SARL Subsidiary · Luxembourg
    • Azenta Singapore Pte Ltd. Subsidiary · Singapore
    • Azenta Switzerland AG Subsidiary · Switzerland
    • Azenta UK Ltd Subsidiary · United Kingdom
    • B Medical Systems India Private Limited Subsidiary · India
    • B Medical Systems SARL Subsidiary · Luxembourg
    • Barkey (Shanghai) Electronic Technology Co. Ltd. Subsidiary · China
    • Barkey Beteiligungsgesellschaft mbH Subsidiary · Germany
    • Barkey GmbH & Co. KG Subsidiary · Germany
    • Barkey Holding GmbH Subsidiary · Germany
    • BioSpeciman Corporation Subsidiary · Canada
    • Cedrex AS Subsidiary · Denmark
    • GENEWIZ (Suzhou), Ltd. Subsidiary · China
    • GENEWIZ France Ltd. Subsidiary · France
    • GENEWIZ Germany GmbH Subsidiary · Germany
    • GENEWIZ UK Ltd. Subsidiary · United Kingdom
    • Ziath B.V. Subsidiary · Netherlands

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Azenta Life Sciences reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Computer equipment and software$38.5M6 Sep 30, 2025$32.8M6 Sep 30, 2024+17.4%
Finance-lease assets$1.2M6 Sep 30, 2025$1.3M6 Sep 30, 2024−6.6%
Operating-lease assets (leased space)$54.0M6 Sep 30, 2025$60.4M6 Sep 30, 2024−10.5%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$279.8M6 Sep 30, 2025$280.0M6 Sep 30, 2024−0.1%
Marketable securities, current$61.1M6 Sep 30, 2025$151.2M6 Sep 30, 2024−59.6%
Marketable securities, non-current$201.6M6 Sep 30, 2025$49.5M6 Sep 30, 2024+307.6%
Debt securities available for sale$262.7M6 Sep 30, 2025$200.6M6 Sep 30, 2024+31.0%

Intangibles and goodwill

ItemLatestA year beforeChange
Goodwill$702.4M6 Sep 30, 2025$691.4M6 Sep 30, 2024+1.6%
Finite-lived intangibles, gross$523.2M14 Sep 30, 2024$515.6M14 Sep 30, 2023+1.5%
Accumulated amortization$275.2M14 Sep 30, 2024$221.3M14 Sep 30, 2023+24.3%
Finite-lived intangibles, net$101.8M6 Sep 30, 2025$125.0M6 Sep 30, 2024−18.6%

Inventory

ItemLatestA year beforeChange
Inventory, total$75.0M6 Sep 30, 2025$71.3M6 Sep 30, 2024+5.1%
Work in process$5.0M6 Sep 30, 2025$7.7M6 Sep 30, 2024−34.7%
Finished goods$36.6M6 Sep 30, 2025$36.1M6 Sep 30, 2024+1.3%

Properties, in its own words

Our corporate headquarters are currently located in Burlington, Massachusetts. We maintained the following principal facilities as of September 30, 2025:

Square Footage · Ownership Status/

The rest of Item 2

Location · Functions · Segment · (Approx.) · Lease Expiration

Suzhou, China · Laboratory & office · Multiomics · 240,000 · Owned

Indianapolis, Indiana · Sample storage, sales & support · Sample Management Solutions · 116,700 · September 2043

Billerica, Massachusetts · Sample storage, R&D and office · Sample Management Solutions · 39,900 · October 2033

South Plainfield, New Jersey · Laboratory and office · Multiomics · 73,300 · January 2030

Plainfield, Indiana · Manufacturing, R&D and sales & support · Sample Management Solutions · 67,900 · August 2042

Springfield, Missouri · Manufacturing, R&D and sales & support · Sample Management Solutions · 50,100 · December 2028

Manchester, United Kingdom · Manufacturing and office · Sample Management Solutions · 44,700 · December 2029

Burlington, Massachusetts · Corporate headquarters, training, R&D and sales & support · All · 26,700 · October 2030

In addition to the principal facilities listed above, we maintain additional laboratories, biorepositories, and sales and support offices throughout North America, Europe, and Asia. The Company believes that its facilities are in good physical condition, are suitable and adequate for the operations conducted at those facilities and are generally fully utilized and operating at normal capacity.

Item 2 of the 10-K filed Dec 4, 2025.19

The story

Brooks Automation was set up in 1978, and incorporated in 1994.

Brooks acquired the German company Jenoptik-Infab GmbH, subsidiary of M+W Zander, in 1999 to incorporate its mini-environment technology for 300 mm wafer handling.

In 2002, Brooks Automation, Inc. completed the acquisition of Intelligent Automation Systems, Inc. of Cambridge, Massachusetts, a custom automation company with technology and products for the semiconductor, photonics and life sciences industries.

Brooks Automation acquired the Celigo automated Cell Cytometer product line from Cyntellect, Inc in 2011. The same year, Brooks acquired Nexus Biosystems, which produced compound and sample management systems. The following year the company acquired intangible assets from Intevac, Inc. and acquired Crossing Automation Inc.

In October 2012, Brooks Automation entered into an agreement to acquire Crossing Automation Inc.

In April 2014, Brooks Automation entered into an agreement to sell its Granville-Phillips division to MKS Instruments.

Brooks closed the sale of Granville-Phillips to MKS Instruments on May 30, 2014.

Brooks automation announced the acquisition of Biostorage Technologies on 1 December 2015.

Read the full text

In 2017, Brooks acquired 4titude, a maker of scientific tools and consumables, while in 2018, Brooks acquired GENEWIZ, a genomics services provider as part of their life sciences division's expansion.

In November 2021, Brooks Automation Inc. split into two entities, Brooks Automation and Azenta Life Sciences. The latter will focus exclusively on their life science division.

In August 2022, Azenta Life Sciences has come to a definitive agreement to acquire B Medical Systems S.á.r.l., in a transaction of approx. €410 million (with an additional €50 million in future performance milestones) is expected to be completed by October 2022.

From Wikipedia’s article on Azenta, shared under CC BY-SA 4.0.8

Leadership

Who has led Azenta Life Sciences, and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Edward C. Grady2006–2007
  2. Robert Lepofsky2007–2010
  3. Stephen S. Schwartz2010–2023
  4. John Marotta2024–2026
  5. Martin D. Madaus2026–now

President

  1. Edward C. Grady2006
  2. James Gentilcore2006–2007
  3. Joseph Bellini2006–2007
  4. Michael W. Pippins2008–2009
  5. Ralf K. Wuellner2008–2009
  6. Stephen S. Schwartz2010–2013
  7. Mark D. Morelli2013–2015
  8. Maurice H. Tenney2014–2019
  9. Guojuan Liao2018–2020
  10. David Jarzynka2019–2021
  11. John Marotta2024–now

Chief financial officer

  1. Robert W. Woodbury Jr.2006–2008
  2. Martin S. Headley2008–2013
  3. Lindon G. Robertson2013–2023
  4. Herman Cueto2023–2024
  5. Lawrence Y. Lin2024–now

Chief operating officer

  1. Joseph Bellini2006–2007
  2. James Gentilcore2006–2007
  3. Mark D. Morelli2012–2015
  4. Matthew McManus2022
2010201520202025
Board members and other officers (54)

Products and brands

  • multi-well plate

Listed on Wikidata.1

Business

Brooks Automation operates in three segments: Brooks Product Solutions, Brooks Global Services, and Brooks Life Science Systems.

Brooks Automation provides mainly four kinds: semiconductor automation and life science systems equipment, gas analysis and vacuum measurement, cryopumps, cryochillers and compressors, asset tracking equipment. The company features in developing and building the handling system and related technology. Automation products are used to support both atmospheric and vacuum based processes while the company's focus remains on improving performance and productivity. The company provides vacuum pumps and instrumentation to maintain pressure consistency of the known process gas. The Brooks Life Science Systems provides automated sample management systems and equipment, such as automated blood fractionation equipment, cellular imaging, and consumables parts.

Research and development

In January 2012, Brooks Automation announced that it had acquired the Celigo Cell Cytometer product line from Cyntellect Inc. Celigo had an advantage in cell imaging systems based on its unique combination of high-throughput, ease-of-use, and affordability.

In April 2012, Brooks Automation announced the Polycold Systems XC Cryochiller (a multi-purpose cooler) product line and set a new standard in the industry. With the new production line put into use in vacuum and thermal management applications, it would greatly increase water vapor pumping speed and decrease the operating costs.

Read the full text

In July 2013, Brooks Automation announced that it had signed a definitive agreement to acquire the assets and business of Matrical, Inc.($10 million) to expand the Brooks Life Science Systems business. Matrical focuses on biological sample preparation, management, and storage solutions.

From Wikipedia’s article on Azenta, shared under CC BY-SA 4.0.8

Subsidiaries and ownership

Subsidiaries (Exhibit 21)

  • Azenta (Guangzhou) Life Science Co., Ltd. China9
  • Azenta (Nanjing) Life Science Technologies Co., Ltd. China9
  • Azenta (Shanghai) Life Science Co. Ltd. China9
  • Azenta (Tianjin) Biotechnology Co., Ltd. China9
  • Azenta Beijing Technologies Limited China9
  • Azenta Germany GmbH Germany9
  • Azenta Japan Corp. Japan9
  • Azenta Life Sciences Canada, Inc. Canada9
  • Azenta Luxembourg SARL Luxembourg9
  • Azenta Singapore Pte Ltd. Singapore9
  • Azenta Switzerland AG Switzerland9
  • Azenta UK Ltd UK9
  • B Medical Systems India Private Limited India9
  • B Medical Systems SARL Luxembourg9
  • Barkey (Shanghai) Electronic Technology Co. Ltd. China9
  • Barkey Beteiligungsgesellschaft mbH Germany9
  • Barkey GmbH & Co. KG Germany9
  • Barkey Holding GmbH Germany9
  • BioSpeciman Corporation Canada9
  • Cedrex AS Denmark9
  • GENEWIZ (Suzhou), Ltd. China9
  • GENEWIZ France Ltd. France9
  • GENEWIZ Germany GmbH Germany9
  • GENEWIZ UK Ltd. UK9
All 26 listed subsidiaries
  • Ziath B.V. Netherlands9
  • Ziath Ltd. UK9

The subsidiaries the company lists in Exhibit 21 of its annual report, as filed.

Employees over time

  • 20231,1761

Former names

  • Brooks Automation, Inc.May 28, 2019 to Nov 24, 20217
  • BROOKS-PRI AUTOMATION INCMay 14, 2002 to Feb 14, 20037
  • BROOKS AUTOMATION INCFeb 12, 1996 to May 10, 20197

Timeline

  1. Oct 7, 20268-K Exit or restructuring costs; Impairment93
  2. Sep 17, 20268-K Executive or director change94
  3. Sep 16, 2026New chief executive Martin D. Madaus becomes CEO20
  4. Sep 4, 20268-K Regulation FD disclosure; Other events95
  5. Aug 24, 20268-K Executive or director change; Regulation FD disclosure96
  6. Aug 11, 20268-K Executive or director change97
  7. Aug 4, 20268-K Results of operations98
  8. Jul 8, 20268-K Entered a material agreement; Completed an acquisition or sale; Regulation FD disclosure99
  9. May 5, 20268-K Results of operations100
  10. Apr 7, 20268-K Executive or director change; Regulation FD disclosure101
  11. Apr 2, 20268-K Other events102
  12. Mar 4, 20268-K Entered a material agreement; Regulation FD disclosure103
  13. Feb 4, 20268-K Results of operations104
  14. Sep 11, 2024New chief executive John Marotta becomes CEO21
  15. Dec 6, 2010New chief executive Stephen S. Schwartz becomes CEO22
  16. Nov 13, 2007New chief executive Robert Lepofsky becomes CEO23
  17. Feb 1, 2006New chief executive Edward C. Grady becomes CEO24
  18. Nov 14, 1994Founded Azenta Life Sciences is founded4

Calendar

Coming up

  1. Nov 20, 2026Reports results for the quarter ending Sep/2026105

When it reported results

  1. Aug 4, 2026Reported quarterly or annual results98
  2. May 5, 2026Reported quarterly or annual results100
  3. Feb 4, 2026Reported quarterly or annual results104
  4. Nov 21, 2025Reported quarterly or annual results106
  5. Aug 5, 2025Reported quarterly or annual results107
  6. May 7, 2025Reported quarterly or annual results108
  7. Feb 5, 2025Reported quarterly or annual results109
  8. Jan 30, 2025Reported quarterly or annual results110

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

365 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 59 major events, 224 insider forms, 23 large holders, 39 other. The latest 20:

  1. Oct 7, 20268-K EDGAR
  2. Sep 23, 20264 EDGAR
  3. Sep 17, 20268-K EDGAR
  4. Sep 16, 20264 EDGAR
  5. Sep 16, 20264 EDGAR
  6. Sep 16, 20264 EDGAR
  7. Sep 16, 20264 EDGAR
  8. Sep 16, 20264 EDGAR
  9. Sep 16, 20264 EDGAR
  10. Sep 9, 20263 EDGAR
  11. Sep 4, 20268-K EDGAR
  12. Aug 24, 20268-K EDGAR
  13. Aug 11, 20264 EDGAR
  14. Aug 11, 20268-K EDGAR
  15. Aug 6, 202610-Q EDGAR
  16. Aug 4, 20264 EDGAR
  17. Aug 4, 20268-K EDGAR
  18. Jul 8, 20268-K EDGAR
  19. May 26, 2026SD EDGAR
  20. May 19, 20264 EDGAR

The 365 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

45 open-market trades by officers, directors and large owners since October 2021: 16 buys and 29 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Jul 31, 2026Starr EphraimSVP, Gen Counsel & SecretaryBuy335$24.17$8.1KForm 4
May 18, 2026Cornog William LDirectorBuy10,000$16.38$163.8KForm 4
Sep 10, 2025Marotta JohnPresident and CEOSale316$29.41$9.3KForm 4
Aug 12, 2025Pirogova OlgaSVP and CHROSale1,085$28.54$31.0KForm 4
Aug 12, 2025Zhou GingerSVP and GM, MultiomicsSale1,085$28.54$31.0KForm 4
Aug 11, 2025Lin Lawrence Y.EVP, CFO and TreasurerBuy2,500$27.96$69.9KForm 4
Jun 2, 2025Marotta JohnPresident and CEOBuy1,000$25.99$26.0KForm 4
May 30, 2025Malus Alan JDirectorBuy12,000$26.65$319.8KForm 4
May 20, 2025Cornog William LDirectorBuy2,748$27.37$75.2KForm 4
May 19, 2025Cornog William LDirectorBuy4,152$26.98$112.0KForm 4
May 16, 2025Cornog William LDirectorBuy100$26.50$2.6KForm 4
Feb 3, 2025Hughes ViolettaVP, Chief Accounting OfficerSale317$52.97$16.8KForm 4
Jan 31, 2025Zhou GingerSVP and GM, MultiomicsBuy417$45.88$19.1KForm 4
Nov 19, 2024Pirogova OlgaSVP and CHROSale548$40.07$22.0KForm 4
Nov 19, 2024Hughes ViolettaVP, Chief Accounting OfficerSale163$40.07$6.5KForm 4
Nov 19, 2024Zhou GingerSVP and GM, MultiomicsSale491$40.07$19.7KForm 4
Nov 19, 2024Wang David DongSVP & GM, SMSSale348$40.07$13.9KForm 4
Nov 19, 2024Joseph JasonSVP, General Counsel, Secy.Sale1,139$40.07$45.6KForm 4
Nov 19, 2024Cueto HermanEVP, Chief Financial OfficerSale712$40.07$28.5KForm 4
Nov 19, 2024Marotta JohnPresident and CEOBuy1,250$40.67$50.8KForm 4

All 45 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Executive pay

What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.

YearExecutiveAgeSalaryTotal pay
2025John Marotta46$900.0K$10.4M118
2025Lawrence Lin48$463.2K$3.9M118
2025Ephraim Starr54$191.1K$2.5M118
2025Jason W. Joseph$355.6K$2.3M118
2025Olga Pirogova51$391.7K$1.7M118
2025Ginger Zhou49$410.1K$1.5M118
2025Herman Cueto$100.0K$770.0K118
2024Former Executive Vice President andChief Financial Officer$490.0K$3.6M118
2024Former Senior Vice PresidentGeneral Counsel/Corporate Secretary$454.6K$2.4M118
2024Senior Vice President, PresidentGENEWIZ$386.5K$1.6M118
2024Senior Vice President andChief Human Resources Officer$370.0K$1.5M118
2024President andChief Executive Officer$34.6K$638.8K118
2023Former Senior Vice PresidentGeneral Counsel/Corporate Secretary$431.9K$1.4M118
2023Senior Vice President, PresidentGENEWIZ$323.1K$849.0K118
2023Senior Vice President andChief Human Resources Officer$25.6K118

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
BlackRock, Inc.7,529,450$192.2M0.0%+804,461
Politan Capital Management LP4,622,450$118.0M46.3%No change
Vanguard Portfolio Management LLC2,493,844$63.6M0.0%+43,352
Vanguard Capital Management LLC1,870,174$47.7M0.0%+41,883
State Street Corp1,859,945$47.5M0.0%+97,522
Massachusetts Financial Services Co /ma/1,423,818$36.3M0.0%−364,432
D. E. Shaw & Co., Inc.1,341,164$34.2M0.0%+662,009
Morgan Stanley1,330,194$33.9M0.0%+464,585
Front Street Capital Management, Inc.1,301,398$33.2M3.8%+412,389
Dimensional Fund Advisors LP1,232,473$31.5M0.0%−827,849
Allspring Global Investments Holdings, LLC1,192,008$31.2M0.0%−421,906
Neuberger Berman Group LLC1,131,616$28.9M0.0%+228,221
Geode Capital Management, LLC1,100,849$28.1M0.0%+91,272
American Capital Management Inc1,061,490$27.1M1.2%−234,534
Royce & Associates LP891,419$22.7M0.2%+368,111
Snyder Capital Management L P872,544$22.3M0.4%+839,350
Victory Capital Management Inc854,005$21.8M0.0%+17,298
Ameriprise Financial Inc768,049$19.6M0.0%+508,798
Bank Of America Corp /de/668,398$17.1M0.0%+200,352
Systematic Financial Management LP650,055$16.6M0.3%+92,377
Citadel Advisors LLC595,904$15.2M0.0%+47,540
Charles Schwab Investment Management Inc588,974$15.0M0.0%+61,363
Segall Bryant & Hamill, LLC553,298$14.1M0.2%+74,959
Schroder Investment Management Group536,876$13.7M0.0%+8,564
Nuveen, LLC530,387$13.5M0.0%+377,489

13F reports cover disclosed long positions in U.S. stocks only.

Members of Congress who traded it

9 trades disclosed by members of Congress. “Vs S&P since” is the stock’s change since the trade minus the S&P 500’s.

DateMemberTradeAmountVs S&P sinceFiling
Mar 3, 2026Gilbert Ray Cisneros, Jr.Democratic, HouseBuy$1,001 - $15,000+25.5%Report
Jan 15, 2026Gilbert Ray Cisneros, Jr.Democratic, HouseBuy$1,001 - $15,000−26.1%Report
Oct 9, 2025Gilbert Ray Cisneros, Jr.Democratic, HouseBuy$1,001 - $15,000−7.6%Report
Mar 19, 2025Josh GottheimerDemocratic, HouseSale$1,001 - $15,000+43.4%Report
Sep 15, 2023Josh GottheimerDemocratic, HousePartial sale$1,001 - $15,000+107.4%Report
Jul 14, 2023Josh GottheimerDemocratic, HouseBuy$1,001 - $15,000−96.2%Report
Jun 13, 2023Josh GottheimerDemocratic, HousePartial sale$1,001 - $15,000+102.6%Report
Dec 15, 2021Josh GottheimerDemocratic, HousePartial sale$1,001 - $15,000+129.8%Report
Dec 3, 2021Josh GottheimerDemocratic, HousePartial sale$1,001 - $15,000+138.2%Report

Members report amounts as ranges, not exact figures. Returns are price-only (no dividends).

SEC filer profile

How Azenta Life Sciences is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARAzenta, Inc.2
  • CIK0000933974
  • Employer ID (EIN)04-304066019
  • Filer statusLarge accelerated filer not an emerging growth company; not a smaller reporting company; not a shell company19
  • Incorporated inDelaware19
  • Fiscal year endsSeptember 302
  • Industry code (SIC)3559 Special Industry Machinery, NEC2
  • SEC reviewing officeOffice of Technology, Division of Corporation Finance2
  • Business address200 Summit Drive, 6Th Floor, Burlington, MA 018032
  • Phone(978) 262-24002
  • Shares outstanding43,808,393 as of Aug 3, 202617
  • Public float$1.0B as of Mar 31, 202519
  • AuditorPricewaterhouseCoopers LLP, Boston, Massachusetts PCAOB ID 238; it also attests to the company’s internal control over financial reporting19
  • On EDGAR sinceFeb 12, 19962
  • Filings2,085 in all: 4 (1,113), 8-K (278), SC 13G/A (113), 10-Q (92), 3 (67), SC 13G (59), 10-K (30), S-8 (30)2
    All 45 form types

    DEF 14A (29), 4/A (20), 425 (20), DEFA14A (20), S-8 POS (19), S-3 (17), 424B1 (16), SC 13D/A (16), 144 (15), 424B3 (15), 8-K/A (14), SD (13), ARS (12), SC TO-I/A (7), UPLOAD (7), 10-K/A (6), 10-Q/A (5), S-3/A (5), S-4/A (5), SC 13D (5), CORRESP (4), S-4 (4), SCHEDULE 13G/A (4), NT 10-K (3), SC TO-C (3), 3/A (2), 8-A12G/A (2), EFFECT (2), NT 10-Q (2), PRE 14A (2), S-3ASR (2), SC TO-I (2), 424B2 (1), 424B5 (1), 8-A12G (1), DEFR14A (1), SCHEDULE 13G (1)

  • Latest filingsAnnual report (10-K) Dec 4, 2025
    Quarterly report (10-Q) Aug 6, 2026
    Proxy statement (DEF 14A) Dec 18, 2025
    Latest 8-K (8-K) Oct 7, 2026

Securities registered for trading

ClassSymbolExchange
Common Stock, $0.01 par valueAZTANasdaq

From the cover page of the 10-K filed Dec 4, 2025 (Section 12(b) of the Exchange Act).19

Risk factors and legal proceedings

The risks Azenta Life Sciences names in Item 1A of its 10-K filed Dec 4, 2025: 33 risks under these headings, as written.19

  • Factors That May Affect Future Results
  • Macroeconomic and External Risks
  • Risks Relating to Our Operations
  • Risks Related to Gene Synthesis
  • Risks Related to Cybersecurity and Data Privacy
  • Risks Related to Geopolitical Tensions and Supply Chain
  • Risks Related to Artificial Intelligence
  • Risks Related to Intellectual Property
  • Risks Related to Reliance on Third Parties
  • Risks Relating to Our Customers
  • Risks Relating to Owning Our Securities
  • A prolonged downturn in macroeconomic conditions may materially adversely affect our business.
The other 32 risks
  • We are subject to risks associated with public health threats and epidemics.
  • Global climate change and related legal and regulatory developments could negatively affect our business, financial condition and results of operations.
  • Unfavorable currency exchange rate fluctuations may impact our significant foreign currency holdings, lead to lower operating margins, or may cause us to raise prices for our products and services, which could result in reduced sales.
  • Our business could be negatively impacted by environmental, social and governance (ESG) matters.
  • Our operating results could fluctuate significantly, which could negatively impact our business.
  • If we do not achieve our transformation initiative goals, our financial results could be negatively impacted.
  • The global nature of our business exposes us to multiple risks.
  • Our business could be materially harmed if we fail to adequately integrate the operations of the businesses that we have acquired or may acquire.
  • Expanding within current markets introduces new competitors and commercial risks.
  • Changes in key personnel could impair our ability to execute our business strategy.
  • Unexpected events could disrupt our sample storage operations and adversely affect our reputation and results of operations.
  • If our facilities were to experience a significant disruption in operations, our business could be materially harmed, while the failure to estimate customer demand accurately could result in excess or obsolete inventory.
  • We have identified material weaknesses in our internal control over financial reporting which led to a conclusion that our internal control over financial reporting is not effective as of September 30, 2025. Our ability to remediate these material weaknesses, the discovery of additional material weaknesses, and our inability to achieve and maintain effective disclosure controls and procedures and internal control over financial reporting, could adversely affect our results of operations, our stock price and investor confidence in our company.
  • Our goodwill and intangible assets may become impaired.
  • Changes in tax rates or tax regulation could affect results of operations.
  • We may face NOL limitations due to insufficient profits in relevant jurisdictions.
  • We are subject to numerous governmental regulations.
  • Regulations and customer demands related to conflict minerals may adversely affect us.
  • Our business relies on certain critical information systems and a failure or breach of such a system could harm our business and results of operations and, in the event of unauthorized access to a customer’s data or our data, incur significant legal and financial exposure and liabilities.
  • Our actual or perceived failure to comply with data protection laws and regulations could lead to government enforcement actions, private litigation and/or adverse publicity and could negatively affect our business.
  • International trade disputes, including as a result of recently announced tariffs and certain trade restrictions, could result in additional or increased tariffs, export controls or other trade restrictions that may have a material impact on our business.
  • Our failure to protect our intellectual property could adversely affect our future operations.
  • The expiration of our patents over time could lead to an increase in competition and a decline in our revenue.
  • We may be subject to claims of infringement of third-party intellectual property rights, or demands that we license third-party technology, which could result in significant expense and prevent us from using our technology.
  • Our business could be materially harmed if one or more key suppliers fail to continuously deliver key components of acceptable cost and quality.
  • Our business could be adversely affected by a decline in the availability of raw materials.
  • Our external service providers may fail to perform as we expect or may suffer cybersecurity breaches.
  • Customers generally do not make long-term commitments to purchase our products and our customers may cease purchasing our products at any time.
  • We may face claims for liability related to damages of customer materials attributed to the failure of our products or services, exposing us to significant financial or reputational harm.
  • Our stock price is volatile.
  • Provisions in our charter documents and Delaware law may delay or prevent an acquisition of us, which could decrease the value of your shares.
  • Our restated certificate of incorporation authorizes the issuance of shares of blank check preferred stock.

Legal proceedings

We are subject to various legal proceedings, both asserted and unasserted, that arise in the ordinary course of business. We cannot predict the ultimate outcome of such legal proceedings or in certain instances provide reasonable ranges of potential losses. However, as of the date of this Annual Report on Form 10-K, we believe that none of these claims will have a material adverse effect on our consolidated financial condition or results of operations. In the event of unexpected subsequent developments and given the inherent unpredictability of these legal proceedings, there can be no assurance that our assessment of any claim will reflect the ultimate outcome and an adverse outcome in certain matters could, from time-to-time, have a material adverse effect on our consolidated financial condition or results of operations in particular quarterly or annual periods. Please refer to Note 3, Discontinued Operations and Note 19, Commitments and Contingencies to our consolidated financial statements included under Part II, Item 8, “Financial Statements and Supplementary Data” of this Annual Report on Form 10 K for more information about our legal proceedings.

The opening of Item 3, Legal Proceedings.19

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57
  58. 58
  59. 59
  60. 60
  61. 61
  62. 62
  63. 63
  64. 64
  65. 65
  66. 66
  67. 67
  68. 68
  69. 69
  70. 70
  71. 71
  72. 72
  73. 73
  74. 74
  75. 75
  76. 76
  77. 77
  78. 78
  79. 79
  80. 80
  81. 81
  82. 82
  83. 83
  84. 84
  85. 85
  86. 86
  87. 87
  88. 88
  89. 89
  90. 90
  91. 91
  92. 92
  93. 93
  94. 94
  95. 95
  96. 96
  97. 97
  98. 98
  99. 99
  100. 100
  101. 101
  102. 102
    SEC EDGAROther events
  103. 103
  104. 104
  105. 105
  106. 106
  107. 107
  108. 108
  109. 109
  110. 110
  111. 111
  112. 112
  113. 113
  114. 114
  115. 115
  116. 116
  117. 117
  118. 118